CD274 and neoplasm: Immunotherapy with antibodies that prevents the binding of Programmed Death Ligand 1 (PD-L1) to its receptor (PD-L1R) has become crucial in a subset of patients with advanced NSCLC, as it has dramatically improved disease-free and overall survival, through innate immune system response against the cancer: binding of PD-1 ligand to its receptors can prevent an innate cytotoxic T-cell response against tumor by inhibiting kinases that are involved in T-cell activation [8].